Table 2.

Summary of proinflammatory and chemoattractant cytokine patterns in patients infected with SARS-CoV-1 and SARS-CoV-2 and following ibrutinib treatment in patients with CLL, WM, or and cGVHD

	He et al¹⁰	Jiang et al¹¹	Huang et al¹³	Niemann et al²¹	Greil et al²⁴	Vos et al²²	Miklos et al²³
Patient population	CoV-1^*	CoV-1^*	CoV-2^*	CLL on ibrutinib^†	CLL on ibrutinib^†	WM on ibrutinib^†	cGVHD on ibrutinib^†
Tissue	ACE2⁺ cells	Plasma	Plasma	Plasma	Plasma	Plasma	Plasma
GM-CSF			↑				↓
IL-1β	↑
IL-2			↑				↓ (IL2RA)
IL-6	↑	↑		↓	↓	↓
IL-7			↑
IL-8		↑		↓	↓	↓	↓
IL-10			↑	↓	↓	Variable
IP-10/CXCL10		↑	↑	↓		↓	↓
MCP-1/CCL2	↑	↑	↑	↓	↓		↓
MIP-1A/CCL3			↑	↓			↓
MIP-1B/CCL4			↑	↓		↓	↓
TNF-α	↑			↓	↓	↓	↓

↑, denotes elevated in patients with SARS-CoV-1 or SARS-CoV-2; ↓, denotes levels decreased or inhibited in patients with the indicated condition with ibrutinib treatment; GM-CSF, granulocyte-macrophage colony-stimulating factor.

Patients infected with SARS-CoV-1 or SARS-CoV-2.

^†

Patients with CLL, WM, or cGVHD.